The critical role of standardised pathological assessment in neoadjuvant therapy for melanoma: A guide for Pathologists | 40 min
1253
students
0
Free
The role of the Pathologist is crucial in the emerging field of neoadjuvant therapy in melanoma. Understanding that their role is fundamental to patient...
Free
Diagnosis and management of uveal melanoma | 44 min
1264
students
0
Free
Despite recent advances in management of primary uveal melanoma, more than half of patients develop metastatic disease – often with poor outcomes. New therapeutic...
Free
Refining pathological response assessment in neoadjuvant therapy for melanoma | 40 min
1300
students
1
Free
In this presentation, Pathologist Prof Richard Scolyer AO discusses how neoadjuvant therapy is transforming melanoma patient care. He also answers key questions around neoadjuvant-treated...
Free
The future of melanoma and surgical oncology | 52 min
1471
students
0
Free
This presentation was recorded at A/Prof Alexander van Akkooi’s inaugural Australian lecture where he discusses his vision and aims for the future of melanoma...
Free
Critical questions for a melanoma pathologist | 36 min
1548
students
0
Free
The role of pathologist in the diagnosis and treatment of melanoma is pivotal to optimal patient care. With so many disciplines relying on the...
Free
Toxicity management in melanoma | 45 min
1677
students
0
Free
Cancer drugs have rapidly evolved in the last decade. Alongside the significant benefits are new toxicity profiles that clinicians need to be aware of...
Free
Update on the adjuvant treatment of melanoma in 2021 | 13 min
1808
students
0
Free
In this presentation, A/Prof Andrew Haydon reviews the efficacy data from 6 large-scale Phase III studies that are looking at the use of modern...
Free
Staging melanoma and bulky palpable Stage III melanoma – is surgery necessary? | 10 min
1808
students
0
Free
In this presentation, A/Prof Sydney Ch’ng discovers the current recommendations for sentinel node biopsy and the implications of high-risk Stage II melanoma trial findings....
Free
Management of in-transit melanoma in the time of active systemic therapy | 11 min
1808
students
0
Free
With up to 14% of patients developing in-transit disease and biologically diverse pathobiological behaviour is observed, in-transit disease is a significant clinical burden. In...
Free